CN107207521A - 作为沉默调节蛋白调节剂的取代的桥连脲类似物 - Google Patents

作为沉默调节蛋白调节剂的取代的桥连脲类似物 Download PDF

Info

Publication number: CN107207521A
Authority: CN; China
Prior art keywords: straight; compound; branched; sirtuin; heteroaryl
Prior art date: 2014-11-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN201580073782.4A

Other languages

English (en)

Chinese (zh)

Inventor

J.L.埃利斯

K.A.埃文斯

R.M.福克斯

W.H.米勒

M.A.塞费尔德

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

GlaxoSmithKline Intellectual Property No 2 Ltd

Original Assignee

GlaxoSmithKline Intellectual Property No 2 Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-11-19

Filing date

2015-11-19

Publication date

2017-09-26

2015-11-19 Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd

2017-09-26 Publication of CN107207521A publication Critical patent/CN107207521A/zh

Status Pending legal-status Critical Current

Links

239000003795 chemical substances by application Substances 0.000 title claims abstract description 77
102000011990 Sirtuin Human genes 0.000 title abstract description 324
108050002485 Sirtuin Proteins 0.000 title abstract description 324
230000003750 conditioning effect Effects 0.000 title abstract description 26
150000003672 ureas Chemical class 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 425
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 151
238000000034 method Methods 0.000 claims abstract description 145
201000010099 disease Diseases 0.000 claims abstract description 134
239000003814 drug Substances 0.000 claims abstract description 89
150000003839 salts Chemical class 0.000 claims abstract description 74
206010012601 diabetes mellitus Diseases 0.000 claims abstract description 39
230000001965 increasing effect Effects 0.000 claims abstract description 38
206010028980 Neoplasm Diseases 0.000 claims abstract description 36
201000011510 cancer Diseases 0.000 claims abstract description 34
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 33
230000035882 stress Effects 0.000 claims abstract description 31
206010061218 Inflammation Diseases 0.000 claims abstract description 26
230000032683 aging Effects 0.000 claims abstract description 26
230000004054 inflammatory process Effects 0.000 claims abstract description 26
230000004770 neurodegeneration Effects 0.000 claims abstract description 26
208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 25
230000000694 effects Effects 0.000 claims description 170
239000001257 hydrogen Substances 0.000 claims description 86
229910052739 hydrogen Inorganic materials 0.000 claims description 86
125000003118 aryl group Chemical group 0.000 claims description 61
108010041191 Sirtuin 1 Proteins 0.000 claims description 55
229910052736 halogen Inorganic materials 0.000 claims description 45
150000002367 halogens Chemical class 0.000 claims description 44
150000002431 hydrogen Chemical class 0.000 claims description 43
125000001424 substituent group Chemical group 0.000 claims description 34
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 31
206010022489 Insulin Resistance Diseases 0.000 claims description 30
125000001072 heteroaryl group Chemical group 0.000 claims description 30
238000006467 substitution reaction Methods 0.000 claims description 30
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 25
229910052799 carbon Inorganic materials 0.000 claims description 22
230000009467 reduction Effects 0.000 claims description 22
230000008859 change Effects 0.000 claims description 20
150000003254 radicals Chemical class 0.000 claims description 20
125000004093 cyano group Chemical group *C#N 0.000 claims description 17
125000000217 alkyl group Chemical group 0.000 claims description 16
125000003545 alkoxy group Chemical group 0.000 claims description 15
238000002560 therapeutic procedure Methods 0.000 claims description 15
201000004681 Psoriasis Diseases 0.000 claims description 12
230000003213 activating effect Effects 0.000 claims description 12
230000009885 systemic effect Effects 0.000 claims description 11
208000001145 Metabolic Syndrome Diseases 0.000 claims description 9
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 9
206010003246 arthritis Diseases 0.000 claims description 9
208000027866 inflammatory disease Diseases 0.000 claims description 9
230000003818 metabolic dysfunction Effects 0.000 claims description 9
201000008937 atopic dermatitis Diseases 0.000 claims description 8
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 7
206010012438 Dermatitis atopic Diseases 0.000 claims description 7
208000001132 Osteoporosis Diseases 0.000 claims description 7
206010040047 Sepsis Diseases 0.000 claims description 7
230000014509 gene expression Effects 0.000 claims description 7
208000013223 septicemia Diseases 0.000 claims description 6
208000002874 Acne Vulgaris Diseases 0.000 claims description 5
206010000496 acne Diseases 0.000 claims description 5
235000013532 brandy Nutrition 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
230000002757 inflammatory effect Effects 0.000 claims description 2
102000000344 Sirtuin 1 Human genes 0.000 claims 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
206010025482 malaise Diseases 0.000 claims 1
-1 urea analog compounds Chemical class 0.000 abstract description 100
238000011282 treatment Methods 0.000 abstract description 69
238000006243 chemical reaction Methods 0.000 abstract description 31
229940124597 therapeutic agent Drugs 0.000 abstract description 24
208000008589 Obesity Diseases 0.000 abstract description 21
235000020824 obesity Nutrition 0.000 abstract description 21
230000002438 mitochondrial effect Effects 0.000 abstract description 17
230000004083 survival effect Effects 0.000 abstract description 17
230000002265 prevention Effects 0.000 abstract description 16
230000008901 benefit Effects 0.000 abstract description 15
208000015294 blood coagulation disease Diseases 0.000 abstract description 6
230000033228 biological regulation Effects 0.000 description 174
239000000203 mixture Substances 0.000 description 116
210000004027 cell Anatomy 0.000 description 103
239000002585 base Substances 0.000 description 57
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 55
102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 53
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 43
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
230000000875 corresponding effect Effects 0.000 description 39
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
125000004429 atom Chemical group 0.000 description 36
102100030710 NAD-dependent protein deacetylase sirtuin-3, mitochondrial Human genes 0.000 description 35
239000007787 solid Substances 0.000 description 35
239000000243 solution Substances 0.000 description 35
108091005770 SIRT3 Proteins 0.000 description 34
238000012360 testing method Methods 0.000 description 33
239000000376 reactant Substances 0.000 description 32
239000000758 substrate Substances 0.000 description 32
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 30
125000002619 bicyclic group Chemical group 0.000 description 29
238000002360 preparation method Methods 0.000 description 29
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 27
101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 26
150000001413 amino acids Chemical class 0.000 description 25
230000006378 damage Effects 0.000 description 25
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 24
235000019439 ethyl acetate Nutrition 0.000 description 24
239000000126 substance Substances 0.000 description 24
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 23
239000000463 material Substances 0.000 description 22
210000003470 mitochondria Anatomy 0.000 description 22
240000004808 Saccharomyces cerevisiae Species 0.000 description 20
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 20
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 20
230000015572 biosynthetic process Effects 0.000 description 20
235000019441 ethanol Nutrition 0.000 description 20
239000012071 phase Substances 0.000 description 19
239000000047 product Substances 0.000 description 19
208000027418 Wounds and injury Diseases 0.000 description 18
239000003153 chemical reaction reagent Substances 0.000 description 18
125000000623 heterocyclic group Chemical group 0.000 description 18
208000006011 Stroke Diseases 0.000 description 17
239000002253 acid Substances 0.000 description 17
210000004369 blood Anatomy 0.000 description 17
239000008280 blood Substances 0.000 description 17
210000003169 central nervous system Anatomy 0.000 description 17
125000004435 hydrogen atom Chemical group [H]* 0.000 description 17
108090000765 processed proteins & peptides Proteins 0.000 description 17
238000003786 synthesis reaction Methods 0.000 description 17
210000001519 tissue Anatomy 0.000 description 17
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
206010008190 Cerebrovascular accident Diseases 0.000 description 16
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 16
208000011580 syndromic disease Diseases 0.000 description 16
241001465754 Metazoa Species 0.000 description 15
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 15
210000001508 eye Anatomy 0.000 description 15
229910052757 nitrogen Inorganic materials 0.000 description 15
241000196324 Embryophyta Species 0.000 description 14
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
230000023555 blood coagulation Effects 0.000 description 14
125000002837 carbocyclic group Chemical group 0.000 description 14
102000034356 gene-regulatory proteins Human genes 0.000 description 14
108091006104 gene-regulatory proteins Proteins 0.000 description 14
230000002829 reductive effect Effects 0.000 description 14
238000003756 stirring Methods 0.000 description 14
BHHMPZQRVWVAAR-UHFFFAOYSA-N 7-bromo-8-methylpyrido[2,3-b]pyrazine Chemical compound C1=CN=C2C(C)=C(Br)C=NC2=N1 BHHMPZQRVWVAAR-UHFFFAOYSA-N 0.000 description 13
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 13
230000006907 apoptotic process Effects 0.000 description 13
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 13
229940079593 drug Drugs 0.000 description 13
238000009472 formulation Methods 0.000 description 13
239000010410 layer Substances 0.000 description 13
239000007788 liquid Substances 0.000 description 13
201000006417 multiple sclerosis Diseases 0.000 description 13
210000003205 muscle Anatomy 0.000 description 13
108090000623 proteins and genes Proteins 0.000 description 13
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
102000003964 Histone deacetylase Human genes 0.000 description 12
108090000353 Histone deacetylase Proteins 0.000 description 12
241000282414 Homo sapiens Species 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
210000004556 brain Anatomy 0.000 description 12
208000014674 injury Diseases 0.000 description 12
239000002904 solvent Substances 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
230000021736 acetylation Effects 0.000 description 11
238000006640 acetylation reaction Methods 0.000 description 11
125000000392 cycloalkenyl group Chemical group 0.000 description 11
125000000753 cycloalkyl group Chemical group 0.000 description 11
239000012634 fragment Substances 0.000 description 11
102000039446 nucleic acids Human genes 0.000 description 11
108020004707 nucleic acids Proteins 0.000 description 11
150000007523 nucleic acids Chemical class 0.000 description 11
102000004196 processed proteins & peptides Human genes 0.000 description 11
210000001525 retina Anatomy 0.000 description 11
208000024891 symptom Diseases 0.000 description 11
LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 10
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 10
206010038923 Retinopathy Diseases 0.000 description 10
208000007536 Thrombosis Diseases 0.000 description 10
238000007792 addition Methods 0.000 description 10
125000003342 alkenyl group Chemical group 0.000 description 10
125000000304 alkynyl group Chemical group 0.000 description 10
239000012043 crude product Substances 0.000 description 10
230000004438 eyesight Effects 0.000 description 10
230000000302 ischemic effect Effects 0.000 description 10
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 10
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 10
239000003921 oil Substances 0.000 description 10
235000019198 oils Nutrition 0.000 description 10
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
239000012453 solvate Substances 0.000 description 10
239000000725 suspension Substances 0.000 description 10
238000004809 thin layer chromatography Methods 0.000 description 10
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
101000616727 Homo sapiens NAD-dependent protein deacylase sirtuin-5, mitochondrial Proteins 0.000 description 9
241000124008 Mammalia Species 0.000 description 9
102100022913 NAD-dependent protein deacetylase sirtuin-2 Human genes 0.000 description 9
102100021839 NAD-dependent protein deacylase sirtuin-5, mitochondrial Human genes 0.000 description 9
108010041216 Sirtuin 2 Proteins 0.000 description 9
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
125000004432 carbon atom Chemical group C* 0.000 description 9
230000030833 cell death Effects 0.000 description 9
238000011284 combination treatment Methods 0.000 description 9
238000005859 coupling reaction Methods 0.000 description 9
239000000706 filtrate Substances 0.000 description 9
239000008103 glucose Substances 0.000 description 9
125000006574 non-aromatic ring group Chemical group 0.000 description 9
238000012545 processing Methods 0.000 description 9
101000616738 Homo sapiens NAD-dependent protein deacetylase sirtuin-6 Proteins 0.000 description 8
101000863629 Homo sapiens NAD-dependent protein lipoamidase sirtuin-4, mitochondrial Proteins 0.000 description 8
102100021840 NAD-dependent protein deacetylase sirtuin-6 Human genes 0.000 description 8
102100030709 NAD-dependent protein lipoamidase sirtuin-4, mitochondrial Human genes 0.000 description 8
208000017442 Retinal disease Diseases 0.000 description 8
150000001412 amines Chemical class 0.000 description 8
239000007864 aqueous solution Substances 0.000 description 8
239000000460 chlorine Substances 0.000 description 8
230000008878 coupling Effects 0.000 description 8
238000010168 coupling process Methods 0.000 description 8
230000004064 dysfunction Effects 0.000 description 8
235000013601 eggs Nutrition 0.000 description 8
238000004128 high performance liquid chromatography Methods 0.000 description 8
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
230000001988 toxicity Effects 0.000 description 8
231100000419 toxicity Toxicity 0.000 description 8
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 8
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
MUXOBHXGJLMRAB-UHFFFAOYSA-N Dimethyl succinate Chemical compound COC(=O)CCC(=O)OC MUXOBHXGJLMRAB-UHFFFAOYSA-N 0.000 description 7
241000282326 Felis catus Species 0.000 description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
239000004202 carbamide Substances 0.000 description 7
230000006735 deficit Effects 0.000 description 7
238000001647 drug administration Methods 0.000 description 7
150000002148 esters Chemical class 0.000 description 7
239000003925 fat Substances 0.000 description 7
235000019197 fats Nutrition 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
230000033001 locomotion Effects 0.000 description 7
230000001404 mediated effect Effects 0.000 description 7
229910052760 oxygen Inorganic materials 0.000 description 7
210000001428 peripheral nervous system Anatomy 0.000 description 7
208000033808 peripheral neuropathy Diseases 0.000 description 7
230000004044 response Effects 0.000 description 7
239000012266 salt solution Substances 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
229910002027 silica gel Inorganic materials 0.000 description 7
229960001866 silicon dioxide Drugs 0.000 description 7
210000003491 skin Anatomy 0.000 description 7
229910052938 sodium sulfate Inorganic materials 0.000 description 7
231100001274 therapeutic index Toxicity 0.000 description 7
229910000404 tripotassium phosphate Inorganic materials 0.000 description 7
208000024827 Alzheimer disease Diseases 0.000 description 6
229920000858 Cyclodextrin Polymers 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
101000709248 Homo sapiens NAD-dependent protein deacetylase sirtuin-7 Proteins 0.000 description 6
206010020772 Hypertension Diseases 0.000 description 6
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
102100034376 NAD-dependent protein deacetylase sirtuin-7 Human genes 0.000 description 6
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
239000003513 alkali Substances 0.000 description 6
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
239000003054 catalyst Substances 0.000 description 6
238000004113 cell culture Methods 0.000 description 6
239000013078 crystal Substances 0.000 description 6
230000006196 deacetylation Effects 0.000 description 6
238000003381 deacetylation reaction Methods 0.000 description 6
208000030533 eye disease Diseases 0.000 description 6
230000006870 function Effects 0.000 description 6
230000023597 hemostasis Effects 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
239000002502 liposome Substances 0.000 description 6
208000002780 macular degeneration Diseases 0.000 description 6
210000005036 nerve Anatomy 0.000 description 6
239000002773 nucleotide Substances 0.000 description 6
125000003729 nucleotide group Chemical group 0.000 description 6
229910052763 palladium Inorganic materials 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
239000000523 sample Substances 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
239000003053 toxin Substances 0.000 description 6
231100000765 toxin Toxicity 0.000 description 6
238000005160 1H NMR spectroscopy Methods 0.000 description 5
UUOLETYDNTVQDY-UHFFFAOYSA-N 2-chloro-3-nitropyridine Chemical class [O-][N+](=O)C1=CC=CN=C1Cl UUOLETYDNTVQDY-UHFFFAOYSA-N 0.000 description 5
206010003591 Ataxia Diseases 0.000 description 5
201000001320 Atherosclerosis Diseases 0.000 description 5
241000283073 Equus caballus Species 0.000 description 5
241000206602 Eukaryota Species 0.000 description 5
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
241000238631 Hexapoda Species 0.000 description 5
241000725303 Human immunodeficiency virus Species 0.000 description 5
208000023105 Huntington disease Diseases 0.000 description 5
208000022559 Inflammatory bowel disease Diseases 0.000 description 5
208000021642 Muscular disease Diseases 0.000 description 5
201000009623 Myopathy Diseases 0.000 description 5
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
239000007832 Na2SO4 Substances 0.000 description 5
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
206010033307 Overweight Diseases 0.000 description 5
241001494479 Pecora Species 0.000 description 5
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
239000012190 activator Substances 0.000 description 5
230000001154 acute effect Effects 0.000 description 5
125000001931 aliphatic group Chemical group 0.000 description 5
150000001721 carbon Chemical group 0.000 description 5
125000004122 cyclic group Chemical group 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
150000002012 dioxanes Chemical class 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
239000000499 gel Substances 0.000 description 5
201000008980 hyperinsulinism Diseases 0.000 description 5
230000001939 inductive effect Effects 0.000 description 5
XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
239000012280 lithium aluminium hydride Substances 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
230000004060 metabolic process Effects 0.000 description 5
229910052751 metal Inorganic materials 0.000 description 5
239000002184 metal Substances 0.000 description 5
201000001119 neuropathy Diseases 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
239000012044 organic layer Substances 0.000 description 5
239000001301 oxygen Substances 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
239000012049 topical pharmaceutical composition Substances 0.000 description 5
RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 5
238000005406 washing Methods 0.000 description 5
KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
ZNGYAZLUJGLXLM-UHFFFAOYSA-N 1-chloro-3,4-dihydro-2H-pyridine Chemical class ClN1CCCC=C1 ZNGYAZLUJGLXLM-UHFFFAOYSA-N 0.000 description 4
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
JHARVUVBTAAPLA-UHFFFAOYSA-N 2-chloro-4-methyl-3-nitropyridine Chemical class CC1=CC=NC(Cl)=C1[N+]([O-])=O JHARVUVBTAAPLA-UHFFFAOYSA-N 0.000 description 4
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
HVISHQCXMPCGQJ-UHFFFAOYSA-N 6-chloro-3,4-dihydro-1H-pyridin-2-one Chemical class ClC1=CCCC(N1)=O HVISHQCXMPCGQJ-UHFFFAOYSA-N 0.000 description 4
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
208000030507 AIDS Diseases 0.000 description 4
208000023275 Autoimmune disease Diseases 0.000 description 4
241000894006 Bacteria Species 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
201000004624 Dermatitis Diseases 0.000 description 4
208000010412 Glaucoma Diseases 0.000 description 4
206010019280 Heart failures Diseases 0.000 description 4
108010033040 Histones Proteins 0.000 description 4
206010061216 Infarction Diseases 0.000 description 4
102000004877 Insulin Human genes 0.000 description 4
108090001061 Insulin Proteins 0.000 description 4
108010042046 Mitochondrial processing peptidase Proteins 0.000 description 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
208000022873 Ocular disease Diseases 0.000 description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
206010037660 Pyrexia Diseases 0.000 description 4
QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 4
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 4
RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
230000004913 activation Effects 0.000 description 4
ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 4
235000011114 ammonium hydroxide Nutrition 0.000 description 4
235000019789 appetite Nutrition 0.000 description 4
230000036528 appetite Effects 0.000 description 4
238000013459 approach Methods 0.000 description 4
210000001367 artery Anatomy 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
230000037396 body weight Effects 0.000 description 4
235000010338 boric acid Nutrition 0.000 description 4
210000004958 brain cell Anatomy 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
238000002425 crystallisation Methods 0.000 description 4
230000008025 crystallization Effects 0.000 description 4
HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 4
MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 4
XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 4
239000000284 extract Substances 0.000 description 4
230000004927 fusion Effects 0.000 description 4
230000036541 health Effects 0.000 description 4
125000005842 heteroatom Chemical group 0.000 description 4
VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 4
150000002430 hydrocarbons Chemical group 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
238000002513 implantation Methods 0.000 description 4
230000006698 induction Effects 0.000 description 4
230000007574 infarction Effects 0.000 description 4
229940125396 insulin Drugs 0.000 description 4
238000007918 intramuscular administration Methods 0.000 description 4
230000004410 intraocular pressure Effects 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
150000003951 lactams Chemical class 0.000 description 4
239000006210 lotion Substances 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
239000002609 medium Substances 0.000 description 4
208000030159 metabolic disease Diseases 0.000 description 4
201000006938 muscular dystrophy Diseases 0.000 description 4
230000001537 neural effect Effects 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
230000007823 neuropathy Effects 0.000 description 4
235000005152 nicotinamide Nutrition 0.000 description 4
239000011570 nicotinamide Substances 0.000 description 4
239000002674 ointment Substances 0.000 description 4
208000027232 peripheral nervous system disease Diseases 0.000 description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
229910000027 potassium carbonate Inorganic materials 0.000 description 4
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
150000003235 pyrrolidines Chemical class 0.000 description 4
230000005855 radiation Effects 0.000 description 4
238000010992 reflux Methods 0.000 description 4
238000011160 research Methods 0.000 description 4
235000021283 resveratrol Nutrition 0.000 description 4
229940016667 resveratrol Drugs 0.000 description 4
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 4
238000012216 screening Methods 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
238000011287 therapeutic dose Methods 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
229930195735 unsaturated hydrocarbon Natural products 0.000 description 4
WKGHUAZJNBXABN-UHFFFAOYSA-N 3-bromo-2-chloro-6-methyl-5-nitropyridine Chemical compound CC1=NC(Cl)=C(Br)C=C1[N+]([O-])=O WKGHUAZJNBXABN-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
208000031229 Cardiomyopathies Diseases 0.000 description 3
208000002177 Cataract Diseases 0.000 description 3
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 3
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 3
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 3
206010014498 Embolic stroke Diseases 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
206010060378 Hyperinsulinaemia Diseases 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
208000001344 Macular Edema Diseases 0.000 description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
208000003435 Optic Neuritis Diseases 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
208000024777 Prion disease Diseases 0.000 description 3
206010060862 Prostate cancer Diseases 0.000 description 3
208000000236 Prostatic Neoplasms Diseases 0.000 description 3
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 3
ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
208000007014 Retinitis pigmentosa Diseases 0.000 description 3
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
235000012538 ammonium bicarbonate Nutrition 0.000 description 3
239000001099 ammonium carbonate Substances 0.000 description 3
230000001093 anti-cancer Effects 0.000 description 3
239000003429 antifungal agent Substances 0.000 description 3
229940121375 antifungal agent Drugs 0.000 description 3
208000010668 atopic eczema Diseases 0.000 description 3
230000005784 autoimmunity Effects 0.000 description 3
230000007845 axonopathy Effects 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
125000002527 bicyclic carbocyclic group Chemical group 0.000 description 3
125000002618 bicyclic heterocycle group Chemical group 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
239000004327 boric acid Substances 0.000 description 3
229910052796 boron Inorganic materials 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
230000032677 cell aging Effects 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
235000013339 cereals Nutrition 0.000 description 3
239000003610 charcoal Substances 0.000 description 3
210000000038 chest Anatomy 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
235000008504 concentrate Nutrition 0.000 description 3
230000021615 conjugation Effects 0.000 description 3
210000004351 coronary vessel Anatomy 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
238000001035 drying Methods 0.000 description 3
239000003480 eluent Substances 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
239000004210 ether based solvent Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 description 3
238000003818 flash chromatography Methods 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
238000013467 fragmentation Methods 0.000 description 3
238000006062 fragmentation reaction Methods 0.000 description 3
125000001188 haloalkyl group Chemical group 0.000 description 3
210000002216 heart Anatomy 0.000 description 3
235000010299 hexamethylene tetramine Nutrition 0.000 description 3
201000001421 hyperglycemia Diseases 0.000 description 3
230000003451 hyperinsulinaemic effect Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
238000001802 infusion Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
230000001788 irregular Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
230000003902 lesion Effects 0.000 description 3
229960004011 methenamine Drugs 0.000 description 3
239000004530 micro-emulsion Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
125000002950 monocyclic group Chemical group 0.000 description 3
230000003387 muscular Effects 0.000 description 3
229960003966 nicotinamide Drugs 0.000 description 3
229960003512 nicotinic acid Drugs 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
125000002524 organometallic group Chemical group 0.000 description 3
201000008482 osteoarthritis Diseases 0.000 description 3
230000016087 ovulation Effects 0.000 description 3
239000006072 paste Substances 0.000 description 3
239000003208 petroleum Substances 0.000 description 3
150000003053 piperidines Chemical class 0.000 description 3
210000002381 plasma Anatomy 0.000 description 3
125000003367 polycyclic group Chemical group 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
230000000750 progressive effect Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
101150089009 sir2 gene Proteins 0.000 description 3
229910000029 sodium carbonate Inorganic materials 0.000 description 3
210000000278 spinal cord Anatomy 0.000 description 3
210000000130 stem cell Anatomy 0.000 description 3
230000001629 suppression Effects 0.000 description 3
239000003826 tablet Substances 0.000 description 3
230000032258 transport Effects 0.000 description 3
229940099259 vaseline Drugs 0.000 description 3
235000015112 vegetable and seed oil Nutrition 0.000 description 3
239000008158 vegetable oil Substances 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
239000003643 water by type Substances 0.000 description 3
UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 3
210000005253 yeast cell Anatomy 0.000 description 3
OEGPRYNGFWGMMV-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methanol Chemical compound COC1=CC=C(CO)C=C1OC OEGPRYNGFWGMMV-UHFFFAOYSA-N 0.000 description 2
DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
VYXHVRARDIDEHS-UHFFFAOYSA-N 1,5-cyclooctadiene Chemical compound C1CC=CCCC=C1 VYXHVRARDIDEHS-UHFFFAOYSA-N 0.000 description 2
239000004912 1,5-cyclooctadiene Substances 0.000 description 2
UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 2
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
208000007848 Alcoholism Diseases 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
241000256844 Apis mellifera Species 0.000 description 2
206010003694 Atrophy Diseases 0.000 description 2
241000271566 Aves Species 0.000 description 2
102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 2
238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 2
101100365811 Caenorhabditis elegans sir-2.1 gene Proteins 0.000 description 2
229940127291 Calcium channel antagonist Drugs 0.000 description 2
241000282465 Canis Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
206010007559 Cardiac failure congestive Diseases 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 2
206010008616 Cholecystitis and cholelithiasis Diseases 0.000 description 2
208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
206010058202 Cystoid macular oedema Diseases 0.000 description 2
206010067276 Cytotoxic oedema Diseases 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 description 2
206010012434 Dermatitis allergic Diseases 0.000 description 2
208000032131 Diabetic Neuropathies Diseases 0.000 description 2
206010012689 Diabetic retinopathy Diseases 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
208000012661 Dyskinesia Diseases 0.000 description 2
208000032928 Dyslipidaemia Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
208000019878 Eales disease Diseases 0.000 description 2
206010014759 Endometrial neoplasm Diseases 0.000 description 2
241000233866 Fungi Species 0.000 description 2
229930186217 Glycolipid Natural products 0.000 description 2
201000005569 Gout Diseases 0.000 description 2
208000003807 Graves Disease Diseases 0.000 description 2
208000015023 Graves' disease Diseases 0.000 description 2
229910004373 HOAc Inorganic materials 0.000 description 2
208000005176 Hepatitis C Diseases 0.000 description 2
102000006947 Histones Human genes 0.000 description 2
201000002563 Histoplasmosis Diseases 0.000 description 2
101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
208000035150 Hypercholesterolemia Diseases 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
208000027747 Kennedy disease Diseases 0.000 description 2
208000009829 Lewy Body Disease Diseases 0.000 description 2
229910010084 LiAlH4 Inorganic materials 0.000 description 2
208000017170 Lipid metabolism disease Diseases 0.000 description 2
208000031471 Macular fibrosis Diseases 0.000 description 2
206010025415 Macular oedema Diseases 0.000 description 2
206010025421 Macule Diseases 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
201000002169 Mitochondrial myopathy Diseases 0.000 description 2
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
206010029164 Nephrotic syndrome Diseases 0.000 description 2
206010029240 Neuritis Diseases 0.000 description 2
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
208000030768 Optic nerve injury Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
229910019213 POCl3 Inorganic materials 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
206010034719 Personality change Diseases 0.000 description 2
XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
235000014676 Phragmites communis Nutrition 0.000 description 2
IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 description 2
208000033063 Progressive myoclonic epilepsy Diseases 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
208000003782 Raynaud disease Diseases 0.000 description 2
208000012322 Raynaud phenomenon Diseases 0.000 description 2
206010038910 Retinitis Diseases 0.000 description 2
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
208000021811 Sandhoff disease Diseases 0.000 description 2
206010040070 Septic Shock Diseases 0.000 description 2
241000700584 Simplexvirus Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
208000022292 Tay-Sachs disease Diseases 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
206010064930 age-related macular degeneration Diseases 0.000 description 2
238000005054 agglomeration Methods 0.000 description 2
201000007930 alcohol dependence Diseases 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
150000001335 aliphatic alkanes Chemical class 0.000 description 2
150000001345 alkine derivatives Chemical class 0.000 description 2
150000003973 alkyl amines Chemical group 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
229960003805 amantadine Drugs 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000003712 anti-aging effect Effects 0.000 description 2
230000002424 anti-apoptotic effect Effects 0.000 description 2
230000000561 anti-psychotic effect Effects 0.000 description 2
239000000010 aprotic solvent Substances 0.000 description 2
210000001742 aqueous humor Anatomy 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
210000002565 arteriole Anatomy 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
230000037444 atrophy Effects 0.000 description 2
230000008827 biological function Effects 0.000 description 2
230000008512 biological response Effects 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
208000030303 breathing problems Diseases 0.000 description 2
229940006460 bromide ion Drugs 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
206010006451 bronchitis Diseases 0.000 description 2
230000001201 calcium accumulation Effects 0.000 description 2
239000000480 calcium channel blocker Substances 0.000 description 2
230000005907 cancer growth Effects 0.000 description 2
239000007894 caplet Substances 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
230000003915 cell function Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
238000002659 cell therapy Methods 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
230000002113 chemopreventative effect Effects 0.000 description 2
238000005660 chlorination reaction Methods 0.000 description 2
210000003161 choroid Anatomy 0.000 description 2
230000004087 circulation Effects 0.000 description 2
101150018117 cobB gene Proteins 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000011254 conventional chemotherapy Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
210000004087 cornea Anatomy 0.000 description 2
229940099112 cornstarch Drugs 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
210000000695 crystalline len Anatomy 0.000 description 2
125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 2
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 2
238000007872 degassing Methods 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
230000037213 diet Effects 0.000 description 2
235000007882 dietary composition Nutrition 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000007876 drug discovery Methods 0.000 description 2
229960001484 edetic acid Drugs 0.000 description 2
201000003914 endometrial carcinoma Diseases 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
230000001037 epileptic effect Effects 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
230000003492 excitotoxic effect Effects 0.000 description 2
231100000063 excitotoxicity Toxicity 0.000 description 2
238000000605 extraction Methods 0.000 description 2
201000005577 familial hyperlipidemia Diseases 0.000 description 2
239000000835 fiber Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000003292 glue Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
230000012010 growth Effects 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
229940121372 histone deacetylase inhibitor Drugs 0.000 description 2
239000003276 histone deacetylase inhibitor Substances 0.000 description 2
231100000652 hormesis Toxicity 0.000 description 2
244000052637 human pathogen Species 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 2
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
208000023692 inborn mitochondrial myopathy Diseases 0.000 description 2
150000002475 indoles Chemical class 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
150000002596 lactones Chemical class 0.000 description 2
201000010901 lateral sclerosis Diseases 0.000 description 2
231100000518 lethal Toxicity 0.000 description 2
231100000636 lethal dose Toxicity 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
244000144972 livestock Species 0.000 description 2
230000007774 longterm Effects 0.000 description 2
210000002189 macula lutea Anatomy 0.000 description 2
201000010230 macular retinal edema Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
235000013372 meat Nutrition 0.000 description 2
LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 2
230000009245 menopause Effects 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical class COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
244000005700 microbiome Species 0.000 description 2
230000000116 mitigating effect Effects 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
201000005518 mononeuropathy Diseases 0.000 description 2
230000037023 motor activity Effects 0.000 description 2
208000005264 motor neuron disease Diseases 0.000 description 2
230000004118 muscle contraction Effects 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
230000000626 neurodegenerative effect Effects 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
235000001968 nicotinic acid Nutrition 0.000 description 2
239000011664 nicotinic acid Substances 0.000 description 2
229910017604 nitric acid Inorganic materials 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
238000007899 nucleic acid hybridization Methods 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
208000001797 obstructive sleep apnea Diseases 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
239000003883 ointment base Substances 0.000 description 2
206010030875 ophthalmoplegia Diseases 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
210000000578 peripheral nerve Anatomy 0.000 description 2
239000008177 pharmaceutical agent Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
239000006187 pill Substances 0.000 description 2
231100000614 poison Toxicity 0.000 description 2
239000002574 poison Substances 0.000 description 2
201000010065 polycystic ovary syndrome Diseases 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
102000040430 polynucleotide Human genes 0.000 description 2
108091033319 polynucleotide Proteins 0.000 description 2
239000002157 polynucleotide Substances 0.000 description 2
210000003137 popliteal artery Anatomy 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
PMXCMJLOPOFPBT-HNNXBMFYSA-N purvalanol A Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)C(C)C)=NC=1NC1=CC=CC(Cl)=C1 PMXCMJLOPOFPBT-HNNXBMFYSA-N 0.000 description 2
150000003233 pyrroles Chemical class 0.000 description 2
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
229960004622 raloxifene Drugs 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
230000009933 reproductive health Effects 0.000 description 2
230000002207 retinal effect Effects 0.000 description 2
201000007714 retinoschisis Diseases 0.000 description 2
229960000888 rimantadine Drugs 0.000 description 2
SOEDEYVDCDYMMH-UHFFFAOYSA-N robinetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 SOEDEYVDCDYMMH-UHFFFAOYSA-N 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
208000001076 sarcopenia Diseases 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000000697 serotonin reuptake Effects 0.000 description 2
238000004904 shortening Methods 0.000 description 2
239000002356 single layer Substances 0.000 description 2
208000017520 skin disease Diseases 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
230000037078 sports performance Effects 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000005728 strengthening Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
150000005846 sugar alcohols Chemical class 0.000 description 2
239000000829 suppository Substances 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000009466 transformation Effects 0.000 description 2
ROWMQJJMCWDJDT-UHFFFAOYSA-N tribromomethane Chemical compound Br[C](Br)Br ROWMQJJMCWDJDT-UHFFFAOYSA-N 0.000 description 2
ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 description 2
ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
210000001125 vasa nervorum Anatomy 0.000 description 2
208000019553 vascular disease Diseases 0.000 description 2
235000013311 vegetables Nutrition 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
150000003722 vitamin derivatives Chemical class 0.000 description 2
210000004127 vitreous body Anatomy 0.000 description 2
239000001993 wax Substances 0.000 description 2
208000016261 weight loss Diseases 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
JFCBEFFZEOHJDG-MLWJPKLSSA-N (2s)-2,6-diamino-7-oxooctanoic acid Chemical compound CC(=O)C(N)CCC[C@H](N)C(O)=O JFCBEFFZEOHJDG-MLWJPKLSSA-N 0.000 description 1
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical class CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
YUIOPHXTILULQC-UHFFFAOYSA-N 1,4-Dithiane-2,5-diol Chemical compound OC1CSC(O)CS1 YUIOPHXTILULQC-UHFFFAOYSA-N 0.000 description 1
150000000094 1,4-dioxanes Chemical class 0.000 description 1
JVCBVWTTXCNJBJ-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptane Chemical compound C1CC2CCN1C2 JVCBVWTTXCNJBJ-UHFFFAOYSA-N 0.000 description 1
FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
SHCWQWRTKPNTEM-UHFFFAOYSA-N 2,6-dichloro-3-nitropyridine Chemical class [O-][N+](=O)C1=CC=C(Cl)N=C1Cl SHCWQWRTKPNTEM-UHFFFAOYSA-N 0.000 description 1
COAWNPJQKJEHPG-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-1lambda^{4}-chromen-1-ylium chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 COAWNPJQKJEHPG-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
PLGXRTUGMZEVII-UHFFFAOYSA-N 2-chloro-1h-pyrrole Chemical compound ClC1=CC=CN1 PLGXRTUGMZEVII-UHFFFAOYSA-N 0.000 description 1
MZVSTDHRRYQFGI-UHFFFAOYSA-N 2-chloro-4-methylpyridine Chemical class CC1=CC=NC(Cl)=C1 MZVSTDHRRYQFGI-UHFFFAOYSA-N 0.000 description 1
YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
SFLFCQJQOIZMHF-UHFFFAOYSA-N 3,4-dihydro-2h-chromene-2-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)CCC2=C1 SFLFCQJQOIZMHF-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical class COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
YVVUSIMLVPJXMY-UHFFFAOYSA-N 4-phenylcyclohexan-1-ol Chemical class C1CC(O)CCC1C1=CC=CC=C1 YVVUSIMLVPJXMY-UHFFFAOYSA-N 0.000 description 1
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
108091005479 5-HT2 receptors Proteins 0.000 description 1
LHTKOHSKRMBCAY-UHFFFAOYSA-N 6-chloro-1,2,3,4-tetrahydropyridine Chemical class ClC1=CCCCN1 LHTKOHSKRMBCAY-UHFFFAOYSA-N 0.000 description 1
HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
102000009062 ADP Ribose Transferases Human genes 0.000 description 1
108010049290 ADP Ribose Transferases Proteins 0.000 description 1
206010000117 Abnormal behaviour Diseases 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
208000004142 Acute Retinal Necrosis Syndrome Diseases 0.000 description 1
208000001395 Acute radiation syndrome Diseases 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
208000026872 Addison Disease Diseases 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
206010002329 Aneurysm Diseases 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
208000031295 Animal disease Diseases 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
108091023037 Aptamer Proteins 0.000 description 1
241001553178 Arachis glabrata Species 0.000 description 1
241000203069 Archaea Species 0.000 description 1
102000007371 Ataxin-3 Human genes 0.000 description 1
206010061666 Autonomic neuropathy Diseases 0.000 description 1
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
241000283725 Bos Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
241000178343 Butea superba Species 0.000 description 1
MJBPUQUGJNAPAZ-UHFFFAOYSA-N Butine Natural products O1C2=CC(O)=CC=C2C(=O)CC1C1=CC=C(O)C(O)=C1 MJBPUQUGJNAPAZ-UHFFFAOYSA-N 0.000 description 1
XGXKQCRAQKMAAL-UHFFFAOYSA-N C(C)(C)[Fe] Chemical compound C(C)(C)[Fe] XGXKQCRAQKMAAL-UHFFFAOYSA-N 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
241000244203 Caenorhabditis elegans Species 0.000 description 1
101001059929 Caenorhabditis elegans Forkhead box protein O Proteins 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
241000282421 Canidae Species 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
208000002061 Cardiac Conduction System Disease Diseases 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
101000832687 Cavia porcellus 3-alpha-hydroxysteroid sulfotransferase Proteins 0.000 description 1
101000643834 Cavia porcellus 3-beta-hydroxysteroid sulfotransferase Proteins 0.000 description 1
101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
208000003569 Central serous chorioretinopathy Diseases 0.000 description 1
206010008025 Cerebellar ataxia Diseases 0.000 description 1
208000009043 Chemical Burns Diseases 0.000 description 1
208000018380 Chemical injury Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
241000370738 Chlorion Species 0.000 description 1
208000033895 Choreoacanthocytosis Diseases 0.000 description 1
208000002691 Choroiditis Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
241000723346 Cinnamomum camphora Species 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
NJLHHACGWKAWKL-UHFFFAOYSA-N ClP(Cl)=O Chemical group ClP(Cl)=O NJLHHACGWKAWKL-UHFFFAOYSA-N 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000032170 Congenital Abnormalities Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
206010010947 Coordination abnormal Diseases 0.000 description 1
229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
238000006969 Curtius rearrangement reaction Methods 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
230000005778 DNA damage Effects 0.000 description 1
231100000277 DNA damage Toxicity 0.000 description 1
208000001840 Dandruff Diseases 0.000 description 1
206010011891 Deafness neurosensory Diseases 0.000 description 1
206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
206010012455 Dermatitis exfoliative Diseases 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
206010012655 Diabetic complications Diseases 0.000 description 1
206010012688 Diabetic retinal oedema Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical class COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
241000255925 Diptera Species 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
235000001911 Ehretia microphylla Nutrition 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
208000003656 Electric Burns Diseases 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
206010014824 Endotoxic shock Diseases 0.000 description 1
241000792859 Enema Species 0.000 description 1
206010014989 Epidermolysis bullosa Diseases 0.000 description 1
208000001351 Epiretinal Membrane Diseases 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
206010015218 Erythema multiforme Diseases 0.000 description 1
206010015226 Erythema nodosum Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
241000282324 Felis Species 0.000 description 1
102100028075 Fibroblast growth factor 6 Human genes 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
208000024412 Friedreich ataxia Diseases 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
208000036391 Genetic obesity Diseases 0.000 description 1
208000031448 Genomic Instability Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
206010018429 Glucose tolerance impaired Diseases 0.000 description 1
206010018612 Gonorrhoea Diseases 0.000 description 1
ZHPLPRUARZZBET-UHFFFAOYSA-N Gossypetin Natural products O1C2=C(O)C(O)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C(O)=C1 ZHPLPRUARZZBET-UHFFFAOYSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101150021206 HST3 gene Proteins 0.000 description 1
101150077931 HST4 gene Proteins 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
206010019728 Hepatitis alcoholic Diseases 0.000 description 1
206010019972 Herpes viral infections Diseases 0.000 description 1
241000175212 Herpesvirales Species 0.000 description 1
208000005100 Herpetic Keratitis Diseases 0.000 description 1
102000002268 Hexosaminidases Human genes 0.000 description 1
108010000540 Hexosaminidases Proteins 0.000 description 1
ZPFXBGIJKDANBP-UHFFFAOYSA-N Hibiscetin Natural products OC1=C(O)C(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C(O)=C3O2)O)=C1 ZPFXBGIJKDANBP-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000863566 Homo sapiens NAD-dependent protein deacetylase sirtuin-3, mitochondrial Proteins 0.000 description 1
101000667092 Homo sapiens Vacuolar protein sorting-associated protein 13A Proteins 0.000 description 1
208000033830 Hot Flashes Diseases 0.000 description 1
206010060800 Hot flush Diseases 0.000 description 1
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
241000598171 Human adenovirus sp. Species 0.000 description 1
241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010020649 Hyperkeratosis Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010058222 Hypertensive cardiomyopathy Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
208000031773 Insulin resistance syndrome Diseases 0.000 description 1
244000017020 Ipomoea batatas Species 0.000 description 1
235000002678 Ipomoea batatas Nutrition 0.000 description 1
206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
XETQTCAMTVHYPO-UHFFFAOYSA-N Isocamphan von ungewisser Konfiguration Natural products C1CC2C(C)(C)C(C)C1C2 XETQTCAMTVHYPO-UHFFFAOYSA-N 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
206010048804 Kearns-Sayre syndrome Diseases 0.000 description 1
208000001126 Keratosis Diseases 0.000 description 1
206010023379 Ketoacidosis Diseases 0.000 description 1
208000007976 Ketosis Diseases 0.000 description 1
LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
201000002832 Lewy body dementia Diseases 0.000 description 1
229910010082 LiAlH Inorganic materials 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
208000009564 MELAS Syndrome Diseases 0.000 description 1
208000002569 Machado-Joseph Disease Diseases 0.000 description 1
206010054805 Macroangiopathy Diseases 0.000 description 1
206010025412 Macular dystrophy congenital Diseases 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
241001599018 Melanogaster Species 0.000 description 1
208000037093 Menstruation Disturbances Diseases 0.000 description 1
206010027339 Menstruation irregular Diseases 0.000 description 1
206010070909 Metabolic cardiomyopathy Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010053961 Mitochondrial toxicity Diseases 0.000 description 1
206010027918 Mononeuropathy multiplex Diseases 0.000 description 1
206010028116 Mucosal inflammation Diseases 0.000 description 1
201000010927 Mucositis Diseases 0.000 description 1
101100149522 Mus musculus Sirt1 gene Proteins 0.000 description 1
101100477601 Mus musculus Sirt3 gene Proteins 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
108010083674 Myelin Proteins Proteins 0.000 description 1
102000006386 Myelin Proteins Human genes 0.000 description 1
208000009525 Myocarditis Diseases 0.000 description 1
244000132436 Myrica rubra Species 0.000 description 1
IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
VEYYWZRYIYDQJM-ZETCQYMHSA-N N(2)-acetyl-L-lysine Chemical class CC(=O)N[C@H](C([O-])=O)CCCC[NH3+] VEYYWZRYIYDQJM-ZETCQYMHSA-N 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
YPGXBBWRDMCJCM-JIZZDEOASA-N N=NC=NN.N=NC=NN.N[C@H](C(=O)O)CC(=O)O Chemical compound N=NC=NN.N=NC=NN.N[C@H](C(=O)O)CC(=O)O YPGXBBWRDMCJCM-JIZZDEOASA-N 0.000 description 1
108010057466 NF-kappa B Proteins 0.000 description 1
102000003945 NF-kappa B Human genes 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
206010065119 Necrotising herpetic retinopathy Diseases 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
102000011931 Nucleoproteins Human genes 0.000 description 1
108010061100 Nucleoproteins Proteins 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
241000283898 Ovis Species 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
208000009608 Papillomavirus Infections Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
208000005374 Poisoning Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010036105 Polyneuropathy Diseases 0.000 description 1
208000003971 Posterior uveitis Diseases 0.000 description 1
208000001280 Prediabetic State Diseases 0.000 description 1
206010036590 Premature baby Diseases 0.000 description 1
206010063664 Presumed ocular histoplasmosis syndrome Diseases 0.000 description 1
208000032319 Primary lateral sclerosis Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
206010037075 Protozoal infections Diseases 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
108091030071 RNAI Proteins 0.000 description 1
206010068142 Radiation sickness syndrome Diseases 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010038478 Renal lithiasis Diseases 0.000 description 1
206010038687 Respiratory distress Diseases 0.000 description 1
208000002367 Retinal Perforations Diseases 0.000 description 1
201000007527 Retinal artery occlusion Diseases 0.000 description 1
206010057430 Retinal injury Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
235000019485 Safflower oil Nutrition 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
229940078753 Sirtuin inhibitor Drugs 0.000 description 1
208000026214 Skeletal muscle atrophy Diseases 0.000 description 1
206010040799 Skin atrophy Diseases 0.000 description 1
208000028990 Skin injury Diseases 0.000 description 1
108020004459 Small interfering RNA Proteins 0.000 description 1
208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
206010042496 Sunburn Diseases 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
206010053615 Thermal burn Diseases 0.000 description 1
241000218636 Thuja Species 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
206010044269 Toxocariasis Diseases 0.000 description 1
201000005485 Toxoplasmosis Diseases 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010046298 Upper motor neurone lesion Diseases 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
102100039114 Vacuolar protein sorting-associated protein 13A Human genes 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000000260 Warts Diseases 0.000 description 1
208000029977 White Dot Syndromes Diseases 0.000 description 1
102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 1
101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 1
ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
229910007339 Zn(OAc)2 Inorganic materials 0.000 description 1
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000001785 acacia senegal l. willd gum Substances 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000000397 acetylating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
239000011149 active material Substances 0.000 description 1
150000003855 acyl compounds Chemical class 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
230000011759 adipose tissue development Effects 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
239000008272 agar Substances 0.000 description 1
208000002353 alcoholic hepatitis Diseases 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910000272 alkali metal oxide Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
208000002029 allergic contact dermatitis Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
229940043377 alpha-cyclodextrin Drugs 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
125000006242 amine protecting group Chemical group 0.000 description 1
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
229960000528 amlodipine Drugs 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
239000002280 amphoteric surfactant Substances 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
230000002402 anti-lipaemic effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000002460 anti-migrenic effect Effects 0.000 description 1
230000001741 anti-phlogistic effect Effects 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
238000009360 aquaculture Methods 0.000 description 1
244000144974 aquaculture Species 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
210000000576 arachnoid Anatomy 0.000 description 1
150000004982 aromatic amines Chemical class 0.000 description 1
150000004945 aromatic hydrocarbons Chemical group 0.000 description 1
150000008378 aryl ethers Chemical class 0.000 description 1
150000001502 aryl halides Chemical class 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
210000000467 autonomic pathway Anatomy 0.000 description 1
229960005193 avobenzone Drugs 0.000 description 1
125000002393 azetidinyl group Chemical group 0.000 description 1
201000007917 background diabetic retinopathy Diseases 0.000 description 1
235000013405 beer Nutrition 0.000 description 1
RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
239000012965 benzophenone Substances 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
229960004853 betadex Drugs 0.000 description 1
238000012742 biochemical analysis Methods 0.000 description 1
239000012620 biological material Substances 0.000 description 1
YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
229960003003 biperiden Drugs 0.000 description 1
230000007698 birth defect Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
208000002352 blister Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
125000005619 boric acid group Chemical class 0.000 description 1
229930006742 bornane Natural products 0.000 description 1
GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
229960001467 bortezomib Drugs 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000003461 brachial plexus Anatomy 0.000 description 1
201000006431 brachial plexus neuropathy Diseases 0.000 description 1
230000007177 brain activity Effects 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
201000005845 branch retinal artery occlusion Diseases 0.000 description 1
235000008429 bread Nutrition 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
235000020934 caloric restriction Nutrition 0.000 description 1
BEWYHVAWEKZDPP-UHFFFAOYSA-N camphane Natural products C1CC2(C)CCC1C2(C)C BEWYHVAWEKZDPP-UHFFFAOYSA-N 0.000 description 1
229930008380 camphor Natural products 0.000 description 1
229960000846 camphor Drugs 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
230000009084 cardiovascular function Effects 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
230000004715 cellular signal transduction Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
208000025434 cerebellar degeneration Diseases 0.000 description 1
210000003591 cerebellar nuclei Anatomy 0.000 description 1
201000004559 cerebral degeneration Diseases 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
150000001793 charged compounds Chemical class 0.000 description 1
UXJFDYIHRJGPFS-WPWMEQJKSA-N chembl380797 Chemical compound C=1C=CC=C(\N=C\C=2C3=CC=CC=C3C=CC=2O)C=1C(=O)NC(C)C1=CC=CC=C1 UXJFDYIHRJGPFS-WPWMEQJKSA-N 0.000 description 1
229910052729 chemical element Inorganic materials 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000004296 chiral HPLC Methods 0.000 description 1
KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
201000008675 chorea-acanthocytosis Diseases 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
210000004240 ciliary body Anatomy 0.000 description 1
230000001886 ciliary effect Effects 0.000 description 1
229940114081 cinnamate Drugs 0.000 description 1
238000005352 clarification Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000011436 cob Substances 0.000 description 1
230000006999 cognitive decline Effects 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
239000002131 composite material Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
150000003950 cyclic amides Chemical class 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
201000010206 cystoid macular edema Diseases 0.000 description 1
208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
230000001934 delay Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 description 1
230000003210 demyelinating effect Effects 0.000 description 1
238000000151 deposition Methods 0.000 description 1
238000009795 derivation Methods 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
238000013461 design Methods 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
201000011190 diabetic macular edema Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical compound C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
BYHXBBOSJKPUJL-BYPYZUCNSA-N dimethyl (2s)-2-aminobutanedioate Chemical class COC(=O)C[C@H](N)C(=O)OC BYHXBBOSJKPUJL-BYPYZUCNSA-N 0.000 description 1
FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
208000016097 disease of metabolism Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000003683 electrophilic halogenation reaction Methods 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
231100000284 endotoxic Toxicity 0.000 description 1
230000002346 endotoxic effect Effects 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940095399 enema Drugs 0.000 description 1
150000002085 enols Chemical group 0.000 description 1
210000001339 epidermal cell Anatomy 0.000 description 1
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
239000010696 ester oil Substances 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
230000005496 eutectics Effects 0.000 description 1
208000004526 exfoliative dermatitis Diseases 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
235000011990 fisetin Nutrition 0.000 description 1
229930003944 flavone Natural products 0.000 description 1
150000002213 flavones Chemical class 0.000 description 1
235000011949 flavones Nutrition 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
238000007667 floating Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
UHCBBWUQDAVSMS-UHFFFAOYSA-N fluoroethane Chemical compound CCF UHCBBWUQDAVSMS-UHFFFAOYSA-N 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000002431 foraging effect Effects 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
150000004675 formic acid derivatives Chemical class 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
150000002240 furans Chemical class 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
LNTHITQWFMADLM-UHFFFAOYSA-M gallate Chemical compound OC1=CC(C([O-])=O)=CC(O)=C1O LNTHITQWFMADLM-UHFFFAOYSA-M 0.000 description 1
208000001130 gallstones Diseases 0.000 description 1
GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
229940080345 gamma-cyclodextrin Drugs 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
238000001030 gas--liquid chromatography Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
230000030279 gene silencing Effects 0.000 description 1
230000009368 gene silencing by RNA Effects 0.000 description 1
238000012226 gene silencing method Methods 0.000 description 1
210000001905 globus pallidus Anatomy 0.000 description 1
230000001434 glomerular Effects 0.000 description 1
206010061989 glomerulosclerosis Diseases 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
208000026234 goat disease Diseases 0.000 description 1
YRRAGUMVDQQZIY-UHFFFAOYSA-N gossypetin Chemical compound C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C(O)=C2O1 YRRAGUMVDQQZIY-UHFFFAOYSA-N 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000035876 healing Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
239000004312 hexamethylene tetramine Substances 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
125000006038 hexenyl group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical class OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
229940071870 hydroiodic acid Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
208000022368 idiopathic cardiomyopathy Diseases 0.000 description 1
210000003692 ilium Anatomy 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
210000001822 immobilized cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000002584 immunomodulator Effects 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
208000016290 incoordination Diseases 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
208000021267 infertility disease Diseases 0.000 description 1
208000037493 inherited obesity Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000002917 insecticide Substances 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000000554 iris Anatomy 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
208000001875 irritant dermatitis Diseases 0.000 description 1
208000023589 ischemic disease Diseases 0.000 description 1
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
230000003780 keratinization Effects 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
150000004715 keto acids Chemical class 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000006651 lactation Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
208000006443 lactic acidosis Diseases 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000003212 lipotrophic effect Effects 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
231100000863 loss of memory Toxicity 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
208000029233 macular holes Diseases 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
238000013507 mapping Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000013011 mating Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
229960004640 memantine Drugs 0.000 description 1
229960000967 memantine hydrochloride Drugs 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
230000036630 mental development Effects 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
125000005341 metaphosphate group Chemical group 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000008437 mitochondrial biogenesis Effects 0.000 description 1
230000008811 mitochondrial respiratory chain Effects 0.000 description 1
231100000296 mitochondrial toxicity Toxicity 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
201000002003 mononeuritis multiplex Diseases 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
210000002161 motor neuron Anatomy 0.000 description 1
239000010813 municipal solid waste Substances 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
230000004220 muscle function Effects 0.000 description 1
201000000585 muscular atrophy Diseases 0.000 description 1
230000035772 mutation Effects 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
210000005012 myelin Anatomy 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
239000013642 negative control Substances 0.000 description 1
201000009925 nephrosclerosis Diseases 0.000 description 1
208000009928 nephrosis Diseases 0.000 description 1
231100001027 nephrosis Toxicity 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
208000007431 neuroacanthocytosis Diseases 0.000 description 1
208000018360 neuromuscular disease Diseases 0.000 description 1
230000006764 neuronal dysfunction Effects 0.000 description 1
210000004179 neuropil Anatomy 0.000 description 1
201000002165 neuroretinitis Diseases 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
229910017464 nitrogen compound Inorganic materials 0.000 description 1
150000002830 nitrogen compounds Chemical class 0.000 description 1
UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
235000018343 nutrient deficiency Nutrition 0.000 description 1
208000030212 nutrition disease Diseases 0.000 description 1
ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical class CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 1
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
229960001679 octinoxate Drugs 0.000 description 1
229960003921 octisalate Drugs 0.000 description 1
WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000009965 odorless effect Effects 0.000 description 1
229960001699 ofloxacin Drugs 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
210000001328 optic nerve Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
150000002916 oxazoles Chemical class 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000003566 oxetanyl group Chemical group 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
125000005981 pentynyl group Chemical group 0.000 description 1
238000013146 percutaneous coronary intervention Methods 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000000505 pernicious effect Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
IPBVNPXQWQGGJP-UHFFFAOYSA-N phenyl acetate Chemical class CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
229910000073 phosphorus hydride Inorganic materials 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
QPUMEZIFDXYGPG-UHFFFAOYSA-N piperazine 1H-pyrrole Chemical compound N1CCNCC1.N1C=CC=C1 QPUMEZIFDXYGPG-UHFFFAOYSA-N 0.000 description 1
ZTRPYTHOEREHEN-UHFFFAOYSA-N piperazine pyridine Chemical compound N1CCNCC1.N1=CC=CC=C1.N1=CC=CC=C1 ZTRPYTHOEREHEN-UHFFFAOYSA-N 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000005936 piperidyl group Chemical group 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
230000010152 pollination Effects 0.000 description 1
125000004585 polycyclic heterocycle group Chemical group 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
230000007824 polyneuropathy Effects 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
238000012805 post-processing Methods 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
201000009104 prediabetes syndrome Diseases 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical class CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000000506 psychotropic effect Effects 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
239000000111 purinergic antagonist Substances 0.000 description 1
229940121374 purinergic receptor antagonist Drugs 0.000 description 1
150000003214 pyranose derivatives Chemical class 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
150000003217 pyrazoles Chemical class 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
229960001285 quercetin Drugs 0.000 description 1
235000005875 quercetin Nutrition 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000025915 regulation of apoptotic process Effects 0.000 description 1
230000034986 regulation of gene silencing Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
208000004644 retinal vein occlusion Diseases 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
235000005713 safflower oil Nutrition 0.000 description 1
239000003813 safflower oil Substances 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
239000004576 sand Substances 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
210000003786 sclera Anatomy 0.000 description 1
229940116351 sebacate Drugs 0.000 description 1
CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000035807 sensation Effects 0.000 description 1
235000019615 sensations Nutrition 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
231100000879 sensorineural hearing loss Toxicity 0.000 description 1
208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
230000014860 sensory perception of taste Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
206010040560 shock Diseases 0.000 description 1
230000035939 shock Effects 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000004088 simulation Methods 0.000 description 1
101150084733 sir-2.1 gene Proteins 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
230000025185 skeletal muscle atrophy Effects 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
239000002893 slag Substances 0.000 description 1
239000000779 smoke Substances 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
PANBYUAFMMOFOV-UHFFFAOYSA-N sodium;sulfuric acid Chemical compound [Na].OS(O)(=O)=O PANBYUAFMMOFOV-UHFFFAOYSA-N 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
238000010183 spectrum analysis Methods 0.000 description 1
230000007839 spinal cord development Effects 0.000 description 1
ISFPDBUKMJDAJH-UHFFFAOYSA-N splitomicin Chemical compound C1=CC2=CC=CC=C2C2=C1OC(=O)CC2 ISFPDBUKMJDAJH-UHFFFAOYSA-N 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000009168 stem cell therapy Methods 0.000 description 1
238000011476 stem cell transplantation Methods 0.000 description 1
238000009580 stem-cell therapy Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000004575 stone Substances 0.000 description 1
TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
210000004281 subthalamic nucleus Anatomy 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
229960005137 succinic acid Drugs 0.000 description 1
229960002317 succinimide Drugs 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000000516 sunscreening agent Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
208000006379 syphilis Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
238000003419 tautomerization reaction Methods 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
108091035539 telomere Proteins 0.000 description 1
102000055501 telomere Human genes 0.000 description 1
210000003411 telomere Anatomy 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
150000004685 tetrahydrates Chemical class 0.000 description 1
125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
210000003448 thoracic nerve Anatomy 0.000 description 1
201000005665 thrombophilia Diseases 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
229910052718 tin Inorganic materials 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000000844 transformation Methods 0.000 description 1
229910052723 transition metal Inorganic materials 0.000 description 1
150000003624 transition metals Chemical class 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
BAVYZALUXZFZLV-FIBGUPNXSA-N trideuteriomethanamine Chemical compound [2H]C([2H])([2H])N BAVYZALUXZFZLV-FIBGUPNXSA-N 0.000 description 1
150000008648 triflates Chemical class 0.000 description 1
MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
150000004684 trihydrates Chemical class 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
210000005239 tubule Anatomy 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
239000013598 vector Substances 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
230000004393 visual impairment Effects 0.000 description 1
201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000004260 weight control Methods 0.000 description 1
230000037303 wrinkles Effects 0.000 description 1
208000005494 xerophthalmia Diseases 0.000 description 1
229940071104 xylenesulfonate Drugs 0.000 description 1
235000013618 yogurt Nutrition 0.000 description 1
DJWUNCQRNNEAKC-UHFFFAOYSA-L zinc acetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O DJWUNCQRNNEAKC-UHFFFAOYSA-L 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Plural Heterocyclic Compounds (AREA)

CN201580073782.4A 2014-11-19 2015-11-19 作为沉默调节蛋白调节剂的取代的桥连脲类似物 Pending CN107207521A (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462081916P	2014-11-19	2014-11-19
US62/081,916		2014-11-19
PCT/IB2015/058977 WO2016079709A1 (en)	2014-11-19	2015-11-19	Substituted bridged urea analogs as sirtuin modulators

Publications (1)

Publication Number	Publication Date
CN107207521A true CN107207521A (zh)	2017-09-26

Family

ID=54705247

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
CN201580073782.4A Pending CN107207521A (zh)	2014-11-19	2015-11-19	作为沉默调节蛋白调节剂的取代的桥连脲类似物
CN201580073769.9A Pending CN107207520A (zh)	2014-11-19	2015-11-19	作为沉默调节蛋白调节剂的取代的桥环脲类似物
CN201580073311.3A Pending CN107108627A (zh)	2014-11-19	2015-11-19	作为沉默调节蛋白调节剂的取代的桥环脲类似物
CN201580073897.3A Expired - Fee Related CN107207509B (zh)	2014-11-19	2015-11-19	作为沉默调节蛋白调节剂的取代的桥环脲类似物

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
CN201580073769.9A Pending CN107207520A (zh)	2014-11-19	2015-11-19	作为沉默调节蛋白调节剂的取代的桥环脲类似物
CN201580073311.3A Pending CN107108627A (zh)	2014-11-19	2015-11-19	作为沉默调节蛋白调节剂的取代的桥环脲类似物
CN201580073897.3A Expired - Fee Related CN107207509B (zh)	2014-11-19	2015-11-19	作为沉默调节蛋白调节剂的取代的桥环脲类似物

Country Status (21)

Country	Link
US (4)	US10072011B2 (2)
EP (4)	EP3221317B1 (2)
JP (4)	JP6806679B2 (2)
KR (4)	KR20170083134A (2)
CN (4)	CN107207521A (2)
AU (4)	AU2015348941A1 (2)
BR (4)	BR112017010595A2 (2)
CA (4)	CA2968029A1 (2)
CL (1)	CL2017001275A1 (2)
CO (1)	CO2017004994A2 (2)
CR (1)	CR20170209A (2)
DO (1)	DOP2017000123A (2)
EA (1)	EA201791074A1 (2)
ES (1)	ES2823748T3 (2)
IL (1)	IL252252A0 (2)
MX (1)	MX2017006658A (2)
PE (1)	PE20171257A1 (2)
PH (1)	PH12017500913A1 (2)
RU (3)	RU2017120858A (2)
SG (1)	SG11201703824QA (2)
WO (4)	WO2016079709A1 (2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108329388A (zh) *	2018-01-18	2018-07-27	天津市湖滨盘古基因科学发展有限公司	一种人的沉默配型信息调节蛋白突变蛋白及其应用
CN110478339A (zh) *	2019-08-12	2019-11-22	昆明理工大学	紫铆因在制备靶向恢复突变p53构象药物中的应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2016086088A2 (en)	2014-11-25	2016-06-02	Northwestern University	Wound healing through sirt1 overexpression
CN108395436B (zh) *	2018-05-14	2021-01-12	鹤壁市人民医院	一种咪唑并吡嗪医药中间体的制备方法
CN108707150B (zh) *	2018-05-14	2021-04-16	江苏惠利生物科技有限公司	一种咪唑并吡嗪医药中间体的制备方法
KR20220056223A (ko)	2019-09-02	2022-05-04	메르크 파텐트 게엠베하	유기 전계발광 디바이스용 재료
WO2021100059A1 (en) *	2019-11-19	2021-05-27	Lupin Limited	Process for preparing chroman compounds
PT4090654T (pt) *	2020-01-17	2025-10-07	Lupin Ltd	Métodos, processos e intermediários para a preparação de compostos de cromano
CN114890955A (zh) *	2022-06-23	2022-08-12	江西瑞威尔生物科技有限公司	一种n取代吗啉类有机化合物的制备工艺
WO2025194094A1 (en) *	2024-03-15	2025-09-18	The Regents Of The University Of Michigan	Small molecule modulators of sirt5 and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006094210A2 (en) *	2005-03-03	2006-09-08	Sirtris Pharmaceuticals, Inc.	Tetrahydroquinoxalinone sirtuin modulators
CN102725291A (zh) *	2009-10-29	2012-10-10	西特里斯药业公司	作为沉默调节蛋白调节剂的双环吡啶和相关的类似物
WO2014186313A1 (en) *	2013-05-13	2014-11-20	Glaxosmithkline Llc	Substituted bridged urea analogs as sirtuin modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4727064A (en)	1984-04-25	1988-02-23	The United States Of America As Represented By The Department Of Health And Human Services	Pharmaceutical preparations containing cyclodextrin derivatives
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
UA108596C2 (xx)	2007-11-09	2015-05-25		Інгібітори пептиддеформілази
AU2012352442A1 (en) *	2011-12-12	2014-07-03	Smb Innovation Aps	Novel heterocyclic compounds useful in sirtuin binding and modulation

2015
- 2015-11-19 JP JP2017526852A patent/JP6806679B2/ja not_active Expired - Fee Related
- 2015-11-19 CN CN201580073782.4A patent/CN107207521A/zh active Pending
- 2015-11-19 BR BR112017010595-0A patent/BR112017010595A2/pt not_active Application Discontinuation
- 2015-11-19 CA CA2968029A patent/CA2968029A1/en not_active Abandoned
- 2015-11-19 KR KR1020177016278A patent/KR20170083134A/ko not_active Withdrawn
- 2015-11-19 EP EP15801271.6A patent/EP3221317B1/en active Active
- 2015-11-19 EP EP15804601.1A patent/EP3220918A1/en not_active Withdrawn
- 2015-11-19 WO PCT/IB2015/058977 patent/WO2016079709A1/en not_active Ceased
- 2015-11-19 AU AU2015348941A patent/AU2015348941A1/en not_active Abandoned
- 2015-11-19 JP JP2017526965A patent/JP2017534665A/ja active Pending
- 2015-11-19 RU RU2017120858A patent/RU2017120858A/ru unknown
- 2015-11-19 CN CN201580073769.9A patent/CN107207520A/zh active Pending
- 2015-11-19 US US15/527,581 patent/US10072011B2/en not_active Expired - Fee Related
- 2015-11-19 WO PCT/IB2015/058980 patent/WO2016079711A1/en not_active Ceased
- 2015-11-19 EP EP15816522.5A patent/EP3221322A1/en not_active Withdrawn
- 2015-11-19 CR CR20170209A patent/CR20170209A/es unknown
- 2015-11-19 KR KR1020177016280A patent/KR20170083135A/ko not_active Withdrawn
- 2015-11-19 KR KR1020177016279A patent/KR20170087907A/ko not_active Withdrawn
- 2015-11-19 CN CN201580073311.3A patent/CN107108627A/zh active Pending
- 2015-11-19 US US15/527,941 patent/US20180319810A1/en not_active Abandoned
- 2015-11-19 MX MX2017006658A patent/MX2017006658A/es unknown
- 2015-11-19 AU AU2015348944A patent/AU2015348944A1/en not_active Abandoned
- 2015-11-19 RU RU2017120855A patent/RU2017120855A/ru unknown
- 2015-11-19 ES ES15801271T patent/ES2823748T3/es active Active
- 2015-11-19 US US15/527,851 patent/US20190048016A1/en not_active Abandoned
- 2015-11-19 WO PCT/IB2015/058981 patent/WO2016079712A1/en not_active Ceased
- 2015-11-19 KR KR1020177016277A patent/KR20170083133A/ko not_active Withdrawn
- 2015-11-19 JP JP2017526950A patent/JP2017534664A/ja active Pending
- 2015-11-19 BR BR112017010599A patent/BR112017010599A2/pt not_active Application Discontinuation
- 2015-11-19 PE PE2017000883A patent/PE20171257A1/es not_active Application Discontinuation
- 2015-11-19 AU AU2015348942A patent/AU2015348942B2/en not_active Ceased
- 2015-11-19 US US15/527,440 patent/US20170355705A1/en not_active Abandoned
- 2015-11-19 SG SG11201703824QA patent/SG11201703824QA/en unknown
- 2015-11-19 JP JP2017526875A patent/JP2017534663A/ja not_active Withdrawn
- 2015-11-19 CA CA2968027A patent/CA2968027A1/en not_active Abandoned
- 2015-11-19 AU AU2015348943A patent/AU2015348943A1/en not_active Abandoned
- 2015-11-19 CA CA2968030A patent/CA2968030A1/en not_active Abandoned
- 2015-11-19 EP EP15801270.8A patent/EP3221316A1/en not_active Withdrawn
- 2015-11-19 RU RU2017120857A patent/RU2017120857A/ru unknown
- 2015-11-19 WO PCT/IB2015/058978 patent/WO2016079710A1/en not_active Ceased
- 2015-11-19 EA EA201791074A patent/EA201791074A1/ru unknown
- 2015-11-19 CN CN201580073897.3A patent/CN107207509B/zh not_active Expired - Fee Related
- 2015-11-19 BR BR112017010601A patent/BR112017010601A2/pt not_active Application Discontinuation
- 2015-11-19 CA CA2968032A patent/CA2968032A1/en not_active Abandoned
- 2015-11-19 BR BR112017010602A patent/BR112017010602A2/pt not_active Application Discontinuation
2017
- 2017-05-11 IL IL252252A patent/IL252252A0/en unknown
- 2017-05-17 PH PH12017500913A patent/PH12017500913A1/en unknown
- 2017-05-18 DO DO2017000123A patent/DOP2017000123A/es unknown
- 2017-05-18 CL CL2017001275A patent/CL2017001275A1/es unknown
- 2017-05-19 CO CONC2017/0004994A patent/CO2017004994A2/es unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006094210A2 (en) *	2005-03-03	2006-09-08	Sirtris Pharmaceuticals, Inc.	Tetrahydroquinoxalinone sirtuin modulators
CN102725291A (zh) *	2009-10-29	2012-10-10	西特里斯药业公司	作为沉默调节蛋白调节剂的双环吡啶和相关的类似物
WO2014186313A1 (en) *	2013-05-13	2014-11-20	Glaxosmithkline Llc	Substituted bridged urea analogs as sirtuin modulators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108329388A (zh) *	2018-01-18	2018-07-27	天津市湖滨盘古基因科学发展有限公司	一种人的沉默配型信息调节蛋白突变蛋白及其应用
CN110478339A (zh) *	2019-08-12	2019-11-22	昆明理工大学	紫铆因在制备靶向恢复突变p53构象药物中的应用

Also Published As

Publication number	Publication date
JP2017534665A (ja)	2017-11-24
IL252252A0 (en)	2017-07-31
JP2017534663A (ja)	2017-11-24
JP2017534664A (ja)	2017-11-24
EP3220918A1 (en)	2017-09-27
CA2968029A1 (en)	2016-05-26
CR20170209A (es)	2017-07-17
WO2016079709A1 (en)	2016-05-26
US10072011B2 (en)	2018-09-11
PE20171257A1 (es)	2017-08-28
CN107108627A (zh)	2017-08-29
AU2015348943A1 (en)	2017-06-01
ES2823748T3 (es)	2021-05-10
CL2017001275A1 (es)	2017-12-15
CN107207520A (zh)	2017-09-26
RU2017120858A (ru)	2018-12-19
CA2968027A1 (en)	2016-05-26
JP2017534662A (ja)	2017-11-24
BR112017010601A2 (pt)	2017-12-26
KR20170083134A (ko)	2017-07-17
AU2015348942A1 (en)	2017-06-01
PH12017500913A1 (en)	2017-12-04
CO2017004994A2 (es)	2017-09-20
EP3221317A1 (en)	2017-09-27
AU2015348942B2 (en)	2018-07-05
KR20170087907A (ko)	2017-07-31
EP3221322A1 (en)	2017-09-27
DOP2017000123A (es)	2017-08-15
KR20170083133A (ko)	2017-07-17
CN107207509A (zh)	2017-09-26
AU2015348941A1 (en)	2017-06-01
KR20170083135A (ko)	2017-07-17
BR112017010595A2 (pt)	2018-01-02
AU2015348944A1 (en)	2017-06-01
US20170355705A1 (en)	2017-12-14
BR112017010599A2 (pt)	2017-12-26
JP6806679B2 (ja)	2021-01-06
WO2016079711A1 (en)	2016-05-26
US20180319810A1 (en)	2018-11-08
RU2017120855A (ru)	2018-12-19
CA2968030A1 (en)	2016-05-26
WO2016079710A1 (en)	2016-05-26
WO2016079712A1 (en)	2016-05-26
EP3221317B1 (en)	2020-07-22
CN107207509B (zh)	2020-04-21
CA2968032A1 (en)	2016-05-26
US20190048016A1 (en)	2019-02-14
BR112017010602A2 (pt)	2017-12-26
MX2017006658A (es)	2018-01-15
EP3221316A1 (en)	2017-09-27
EA201791074A1 (ru)	2017-10-31
SG11201703824QA (en)	2017-06-29
US20170362234A1 (en)	2017-12-21
RU2017120857A (ru)	2018-12-19

Legal Events

Date	Code	Title	Description
2017-09-26	PB01	Publication
2017-09-26	PB01	Publication
2017-10-27	SE01	Entry into force of request for substantive examination
2017-10-27	SE01	Entry into force of request for substantive examination
2019-06-28	WD01	Invention patent application deemed withdrawn after publication	Application publication date: 20170926
2019-06-28	WD01	Invention patent application deemed withdrawn after publication

Publication	Publication Date	Title
CN107207521A (zh)	2017-09-26	作为沉默调节蛋白调节剂的取代的桥连脲类似物
CN111433200B (zh)	2024-03-22	用于治疗疾病的化合物及其药物组合物
KR102223227B1 (ko)	2021-03-08	Glp-1 수용체 아고니스트 작용을 갖는 피라졸로피리딘 유도체
CN102548557B (zh)	2014-12-24	用于降低β-淀粉状蛋白生成的化合物
JP5832524B2 (ja)	2015-12-16	ピリドン及びアザピリドン化合物、並びにそれらの使用方法
CN104918934B (zh)	2017-12-22	3‑取代的吡唑及其作为dlk抑制剂的用途
CN105899505B (zh)	2018-08-28	用于治疗自身免疫病症的吡唑
CN104470925B (zh)	2017-12-05	作为激酶抑制剂的咪唑并三嗪甲腈
TWI480282B (zh)	2015-04-11	稠合雜環衍生物及其用途
JP6833686B2 (ja)	2021-02-24	サーチュイン調節剤としての置換架橋尿素類似体
CN112105385A (zh)	2020-12-18	Irak降解剂和其用途
CN113924146A (zh)	2022-01-11	用于治疗疾病的新化合物及其药物组合物
CN112955438A (zh)	2021-06-11	蛋白质酪氨酸磷酸酶抑制剂和其使用方法
WO2014078417A1 (en)	2014-05-22	Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
KR20240026911A (ko)	2024-02-29	골수성 세포 2 작용제 상에서 발현되는 유발 수용체로서의 헤테로고리 화합물 및 사용 방법
TW201713663A (zh)	2017-04-16	經雜芳基取代之胺基吡啶化合物
CN103459382B (zh)	2016-06-29	用于抑制pask的杂环化合物
TW200936591A (en)	2009-09-01	Tricyclic compounds and use thereof
WO2021164746A1 (zh)	2021-08-26	取代芳基类化合物
CN110049979A (zh)	2019-07-23	布罗莫结构域抑制剂
JP7080900B2 (ja)	2022-06-06	Ｐｉ３－キナーゼ活性の阻害剤としてのオキセピノピラゾール誘導体
JP2021534152A (ja)	2021-12-09	Ａｓｋ１阻害剤
RU2782375C2 (ru)	2022-10-26	Новые соединения и их фармацевтические композиции для лечения заболеваний
HK40074720B (zh)	2025-01-03	[1,2,4]三唑并[1,5-c]喹唑啉-5-胺
HK40104906A (zh)	2024-08-02	作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法

CN107207521A - 作为沉默调节蛋白调节剂的取代的桥连脲类似物 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=54705247

Family Applications (4)

Family Applications After (3)

Country Status (21)

Cited By (2)

Families Citing this family (8)

Citations (3)

Family Cites Families (4)

Patent Citations (3)

Cited By (2)

Also Published As

Similar Documents

Legal Events